Current Trends,antibacterial peptides

The Antimicrobial Peptide Database (APD), specifically APD6, represents a significant advancement in the field of antimicrobial research. This comprehensive database has been reconfigured and expanded to support the growing need for information on antimicrobial peptides (AMPs). As of March 18, 2025, APD6 housed an impressive 5188 peptides, a substantial increase from previous versions. This collection includes 3306 natural, 1380 synthetic, and 239 predicted AMPs, offering researchers a vast resource for studying these crucial molecules.

The evolution of the APD family of databases underscores the rapid progress in peptide research. The antimicrobial peptide database (APD), first established based on extensive literature searches, has continuously evolved. Early versions, like APD2, contained fewer entries but already highlighted the diverse activities of peptides, such as anticancer peptides, antiviral (including anti-HIV), antifungal, and antibacterial peptides. The current iteration, APD6, builds upon this foundation, providing a robust platform for both established and novel antimicrobial peptides.

APD6 provides the first systematic classification of synthetic and predicted peptides, a crucial development for researchers aiming to design and discover new antimicrobial agents. The expansion of all three categories of peptides – natural, synthetic, and predicted – within the APD6 platform facilitates a deeper understanding of their characteristics and potential applications. This version of the antimicrobial peptide database is designed to promote research and development by deploying an unprecedented amount of data and analytical resources.

Beyond APD6, other valuable databases exist for antimicrobial peptides. DBAASP is another manually-curated database developed to provide the scientific community with information and analytical resources for designing antimicrobial peptides. Similarly, CAMPR4 contains detailed information on AMP sequence, protein definition, accession numbers, activity, source organism, target organisms, and protein family descriptions, further enriching the landscape of available peptide databases. The Antimicrobial Peptides Database (APD), in its various forms, has become a go-to resource for many, and APD6 represents its most advanced iteration.

The APD family of databases has a rich history. APD3, for instance, focused on natural antimicrobial peptides with defined sequence and activity, containing a total of 2619 AMPs. The continuous growth, as evidenced by the antimicrobial peptide database version 6 (APD6) reporting 5680 peptides in 2025, highlights the dynamic nature of this scientific field. The APD family, including the versions available at aps.unmc.edu, has been instrumental in the advancement of antimicrobial peptide research for two decades.

The APD6 database not only offers a vast collection of antimicrobial peptides but also provides information on anticancer, antiviral, antifungal, and antibacterial peptides. This broad scope makes it an invaluable tool for researchers investigating various therapeutic applications of peptides. The systematic classification of both natural and synthetic peptides within APD6 is a key feature that distinguishes it and aids in the identification of promising candidates for drug development. The Antimicrobial Peptides Database is an essential resource for anyone working in this field.